Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5915204 | 0.84 | DAO (0.41) | DAO | |
| SCHEMBL5915168 | 0.84 | NPC1 (0.42) | ALDH1A1CYP3A4 | |
| SCHEMBL4355607 | 0.83 | METAP2 (0.45) | TDP1ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL5915210 | 0.82 | GAA (0.43) | TDP1ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL5915146 | 0.81 | METAP2 (0.39) | TDP1ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL5915177 | 0.80 | TDP1 (0.35) | TDP1ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL5915165 | 0.79 | ALDH1A1 (0.36) | TDP1ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL4211718 | 0.78 | ALDH1A1 (0.40) | TDP1ALDH1A1MAPK1 | |
| SCHEMBL5915140 | 0.78 | TDP1 (0.36) | TDP1ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL4031165 | 0.77 | TDP1 (0.35) | TDP1ALDH1A1CYP3A4TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247280-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2006-11-02 | — | — | US | claimed |
| EP-1379240-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20060247280-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2006-11-02 | — | — | US | disclosed |
| EP-1379240-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002078696-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247280-A1 | Compounds and methods | METAP2, DNPEP, METAP1 | TDP1 3953/4885ALDH1A1 1820/4885CYP3A4 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.